Skip to main content
. Author manuscript; available in PMC: 2011 Jun 2.
Published in final edited form as: Bioconjug Chem. 2009 Jul 2;20(8):1650–1659. doi: 10.1021/bc900206g

Figure 2.

Figure 2

Comparison of G2.5 dendrimer conjugates as agonists at the human P2Y14 receptor. The capacities of G2.5 dendrimer conjugates 3a (◊), 4 (◆), 8 (●), and 10 (○) to inhibit forskolin (30 μM) stimulated cyclic AMP accumulation were quantified in P2Y14–HEK293 cells as described in Methods. Assays were carried out in triplicate, and all experiments were repeated at least three times. Data were pooled and normalized using forskolin-stimulated cyclic AMP accumulation as 100% and IBMX alone as 0%.